Details about Rebecca M. Henderson

Access statistics for papers by Rebecca M. Henderson.

Last updated 2010-04-11. Update your information in the RePEc Author Service.

Short-id: phe120

Working Papers

2013

1. Managers and Market Capitalism
   Harvard Business School Working Papers, Harvard Business School

2006

2. Public & Private Spillovers, Location and the Productivity of Pharmaceutical Research
   NBER Working Papers, National Bureau of Economic Research, Inc View citations (37)

2005

3. Inertia and Incentives: Bridging Organizational Economics and Organizational Theory
   NBER Working Papers, National Bureau of Economic Research, Inc View citations (61)
4. Platform Owner Entry and Innovation in Complementary Markets: Evidence from Intel
   NBER Working Papers, National Bureau of Economic Research, Inc View citations (1)
   See also Journal Article in Journal of Economics & Management Strategy (2007)

1999

5. Balancing Incentives: The Tension Between Basic and Applied Research
   NBER Working Papers, National Bureau of Economic Research, Inc View citations (47)
6. The Diffusion of Science-Driven Drug Discovery: Organizational Change in Pharmaceutical Research
   NBER Working Papers, National Bureau of Economic Research, Inc View citations (23)

1997

7. Public-Private Interaction and the Productivity of Pharmaceutical Research
   NBER Working Papers, National Bureau of Economic Research, Inc View citations (29)

1995

8. Universities as a Source of Commercial Technology: A Detailed Analysis of University Patenting 1965-1988
   NBER Working Papers, National Bureau of Economic Research, Inc View citations (65)
   Also in Working Papers, Tel Aviv (1995) View citations (12)
   See also Journal Article in The Review of Economics and Statistics (1998)

1994

9. Measuring competence?: exploring firm effects in pharmaceutical research
   Working papers, Massachusetts Institute of Technology (MIT), Sloan School of Management View citations (471)
10. Of life cycles real and imaginary: the unexpectedly long old age of optical lithography
    Working papers, Massachusetts Institute of Technology (MIT), Sloan School of Management
    See also Journal Article in Research Policy (1995)
11. The evolution of integrative capability: innovation in cardiovascular drug discovery
    Working papers, Massachusetts Institute of Technology (MIT), Sloan School of Management View citations (58)

1993

12. Racing or spilling?: the determinants of research productivity in ethical drug discovery
    Working papers, Massachusetts Institute of Technology (MIT), Sloan School of Management View citations (2)
13. Scale, Scope and Spillovers: The Determinants of Research Productivity in the Pharmaceutical Industry
    NBER Working Papers, National Bureau of Economic Research, Inc View citations (13)
14. Scale, scope and spillovers: the determinants of research productivity in ethical drug discovery
    Working papers, Massachusetts Institute of Technology (MIT), Sloan School of Management View citations (7)

1992

15. Geographic Localization of Knowledge Spillovers as Evidenced by Patent Citations
    NBER Working Papers, National Bureau of Economic Research, Inc View citations (1101)
16. Ivory Tower Versus Corporate Lab: An Empirical Study of Basic Research and Appropriability
    NBER Working Papers, National Bureau of Economic Research, Inc View citations (42)

Undated

17. Scale, Scope and Spillovers: The Determinants of Research Productivity in Drug Discovery
    Working Papers, Department of Economics, University of Lancaster View citations (51)
    See also Journal Article in RAND Journal of Economics (1996)

Journal Articles

2007

1. Platform Owner Entry and Innovation in Complementary Markets: Evidence from Intel
   Journal of Economics & Management Strategy, 2007, 16, (1), 1-34 View citations (144)
   See also Working Paper (2005)

2005

2. Patent Citations and the Geography of Knowledge Spillovers: A Reassessment: Comment
   American Economic Review, 2005, 95, (1), 461-464 View citations (82)

2003

3. Discontinuities and senior management: assessing the role of recognition in pharmaceutical firm response to biotechnology
   Industrial and Corporate Change, 2003, 12, (2), 203-233 View citations (62)

2001

4. Scale and scope in drug development: unpacking the advantages of size in pharmaceutical research
   Journal of Health Economics, 2001, 20, (6), 1033-1057 View citations (68)

1998

5. Universities As A Source Of Commercial Technology: A Detailed Analysis Of University Patenting, 1965-1988
   The Review of Economics and Statistics, 1998, 80, (1), 119-127 View citations (420)
   See also Working Paper (1995)

1996

6. Scale, Scope, and Spillovers: The Determinants of Research Productivity in Drug Discovery
   RAND Journal of Economics, 1996, 27, (1), 32-59 View citations (424)
   See also Working Paper

1995

7. Of life cycles real and imaginary: The unexpectedly long old age of optical lithography
   Research Policy, 1995, 24, (4), 631-643 View citations (46)
   See also Working Paper (1994)

1994

8. Racing To Invest? The Dynamics of Competition in Ethical Drug Discovery
   Journal of Economics & Management Strategy, 1994, 3, (3), 481-519 View citations (76)

1993

9. Underinvestment and Incompetence as Responses to Radical Innovation: Evidence from the Photolithographic Alignment Equipment Industry
   RAND Journal of Economics, 1993, 24, (2), 248-270 View citations (269)

Chapters

2001

1. Publicly Funded Science and the Productivity of the Pharmaceutical Industry
   A chapter in Innovation Policy and the Economy, Volume 1, 2001, pp 1-34 View citations (17)